FDA approves 3TC and saquinavir. Food and Drug Administration.
Baker
R
R
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004352:Drug Resistance, Microbial / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D019259:Lamivudine; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D019258:Saquinavir; D014481:United States; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011804:Quinolines; D019259:Lamivudine; D016047:Zalcitabine; D019258:Saquinavir